

CALENDAR

5–6 March 2001

Second International Conference on Cancer and the Adolescent

Royal College of Physicians, London, UK

Further information from:

Conference Administrator, Samantha Greshoff. Tel: +44 (0) 20 8333 6311; Fax: +44 (0) 20 8856 3017;

E-mail: sam@greshoff.free-online.co.uk

13–14 March 2001

National Cancer Nursing Conference

Commonwealth Institute,
London, UK

Further information from:

Conference office, Emap Healthcare Events, Greater London House, Hampstead Road, London NW1 7EJ, UK.

Tel: +44(0) 20 7874 0294; E-mail: conference@healthcare.emap.co.uk; Website: http://www.nursingtimes.net/shop/shop_index.asp

24–26 May 2001

First International Symposium on Target Volume Definition in Radiation Oncology

Limburg/Lahn, Germany

Further information from:

Assoc. Prof. Dr IC Kiricuta, Institute for Radiation Oncology, St. Vincenz-Hospital, Limburg/Lahn, Germany.

Tel: +49 6431 292 4598; Fax: +49 6431 292 4163

1–4 July 2001

British Cancer Research Meeting 2001

University of Leeds, UK

Closing date for abstract submission: 16 February 2001

Further information from:

BCRM Secretariat, c/o Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.

Tel: +44(0) 20 8722 4208; Fax: +44(0) 20 8770 1395;

E-mail: bcrm@icr.ac.uk

National Cancer Institute

Alternative Medicine in Cancer: Opening Doors to Research
NCI's Best Case Series Program

Is your complementary or alternative medicine (CAM) helping cancer patients? NCI invites you to submit data from your best cases for review by conventional research and CAM experts.

For details or a submission package, contact:

Office of Cancer Complementary and Alternative Medicine,
National Cancer Institute, NIH, Executive Plaza North,
Suite 102, Bethesda, MD 20892, USA. Tel: +1 (301) 435 7980;
Fax: +1 (301) 480 7980; E-mail: ncioccam-r@mail.nih.gov;
Website: <http://occam.nci.nih.gov>

Notice to Readers

The first November edition, 83(9), of the **British Journal of Cancer** published on the 13th October 2000 carried an advertisement advising readers that Caelyx (liposomal doxorubicin HCl) was licensed for the treatment of ovarian cancer. This advertisement appeared in advance of the licence being granted for this indication.

Caelyx was licensed on the 26th October 2000 for the treatment of advanced ovarian cancer in patients who have failed a first-line platinum-based chemotherapy regimen.

Schering-Plough Ltd, the UK licence holder for Caelyx, apologises for this error.